HIV/AIDS Therapeutics Market to 2018 - Despite Major Patent Expiries, Increased Uptake of Once-a-Day Fixed-dose Combination Drugs to Drive Growth

Nov 9, 2012 - GBI Research - 111 pages
Abstract Table of Contents Companies Request Details Related
PRINT & SHARE
GBI Research, a leading business intelligence provider, has released its latest research, "HIV/AIDS Therapeutics Market to 2018 - Despite Major Patent Expiries, Increased Uptake of Once-a-Day Fixed-dose Combination Drugs to Drive Growth". The report provides insights into the Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome) HIV/AIDS therapeutics market including market forecasts up to 2018. It provides an in-depth analysis of the major marketed products, as well as insights into the HIV/AIDS therapeutics R&D pipeline. The report provides in-depth analysis of the unmet needs, drivers and barriers that affect the global HIV/AIDS therapeutics market. The report analyzes the market for HIV/AIDS therapeutics in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. The report provides branded and generics segmentation in the therapeutic landscape segment. In addition, it analyzes the HIV/AIDS therapeutics market in India, China and Australia. The report discusses the global pipeline for all the HIV/AIDS molecules across various stages of development. The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts.

GBI Research found that the HIV/AIDS therapeutics market in the top seven markets was valued at $13.5 billion in 2011, increasing at a Compound Annual Growth Rate (CAGR) of 12.5% during the 2004-2011 historic period. The market is projected to witness growth of 7% during the 2011-2018 forecast period to reach $21.8 billion. The growth is primarily driven by the increase in the use of single dose multi-class combination drugs such as Atripla, Complera. With the recent launch of Stribild (previously known as Quad), the multi-class combination drugs would drive the market.

Scope of this Report:
  • Annualized market data for the HIV/AIDS therapeutics market from 2004 to 2011, forecast forward to 2018.
  • Analysis of the HIV/AIDS therapeutics market in the leading geographies of the world, which includes the US, the UK, Germany, France, Italy, Spain, and Japan.
  • Analysis of the HIV/AIDS therapeutics market in India, China and Australia.
  • Market characterization of the HIV/AIDS therapeutics market including market size, annual cost of treatment, and treatment usage patterns.
  • Key drivers and barriers that have a significant impact on the market.
  • Coverage of pipeline molecules in various phases of drug development.
  • Competitive benchmarking of leading companies. Key companies studied in this report are Gilead Sciences, Bristol-Myers Squibb, GlaxoSmithKline, Abbott Laboratories, Johnson & Johnson, Merck, and Roche.
  • Key M&A activities and licensing agreements that have taken place between 2008 and up to June 2012 in the global HIV/AIDS therapeutics market.
Reasons to Get this Report:
  • Align your product portfolio to the markets with high growth potential.
  • Develop market-entry and market expansion strategies by identifying the potential region and HIV/AIDS therapeutics market segments poised for strong growth.
  • Create a more tailored country strategy through the understanding of key drivers and barriers of the global HIV/AIDS therapeutics market.
  • Develop key strategic initiatives by understanding the key focus areas and top selling products of leading companies.
  • Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships.

Order This Report


EASY ORDERING
Once you’ve selected your preferred license option, hit ‘order now’ to complete the checkout process using any major credit card, check or wire/bank transfer.
MC, Visa, AMEX, Diners, Discovery, JCB

The Fast Market Research Advantage
Only the Best
All of our research is sourced from the most trusted and established global analysts and consultancies

Client Focused
From start-ups to multinationals, we focus on providing the right research to our diverse client base

Shop Securely
Our US-based customer service team and eCommerce systems adhere to highest data security standards

Industry-leading Customer Support
Individualized assistance from our expert staff is never more than an email or phone call away


About the Publisher
GBI Research provides industry-leading global business intelligence solutions. Their products and services help companies make better business decisions, win business and position themselves more effectively. GBI Research publishes more than 100 research reports each year across a wide range of industries. These reports draw on in-depth primary and secondary research, databases of proprietary in-house data and high quality analysis from their expert teams. GBI Research employs hundreds of highly qualified Analysts across the US, Europe and Asia.